Comparison of chromogranin a and pancreastatin levels in plasma of patients with pancreatic islet cell tumor

Tateishi, Kensuke; Kitayama, Noboru; Matsuoka, Yuji; Funakoshi, Akihiro

doi:10.1016/0024-3205(95)02022-b

Cited by 13 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is in agreement with data from other groups both for pancreastatin and whole molecule CgA. 7,8,13 As pancreastatin is known to correlate with the number of liver metastases, it may be used as an indicator of the progression of metastatic disease in patients with NETs.…”

Section: Discussionsupporting

confidence: 92%

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours

et al. 2008

View full text Add to dashboard Cite

Aim: To assess the value of pancreastatin as a predictive factor for identifying patients with neuroendocrine tumours (NETs) who respond poorly to somatostatin analogues. Methods: A retrospective study of patients with NETs. Patient records from the Northern Ireland Neuroendocrine Tumour Register were interrogated. Those who had pancreastatin concentrations measured on two or more occasions, before and during somatostatin analogue therapy (within the set time-limits) were selected. Data relating to diagnosis, surgery, somatostatin analogue therapy and survival outcome were noted. Data were subjected to univariate and multivariate analysis using Cox proportional hazard model. Results: Fifty-nine patients with gastroenteropancreatic NETs fulfilled the inclusion criteria. Factors associated with a poor survival outcome on univariate analysis were primary tumour site (P ¼ 0.006) and rapid rise in pancreastatin during somatostatin analogue treatment (P , 0.001). In multivariate analysis, highly significant clinical prognostic indicators were: tumour location (P , 0.001), pre-treatment pancreastatin (P , 0.001) and pancreastatin change (P , 0.001).Conclusions: This study endorses the finding that pancreastatin is a useful prognostic indicator of neuroendocrine disease. On commencement of treatment, one-third of the subjects showed an immediate negative pancreastatin response to somatostatin analogues, which was associated with poor survival. This is the first study to document such an association. These findings have significant therapeutic consequences. In the presence of a rapidly rising pancreastatin alternative, treatment modalities should be sought.

show abstract

Section: Discussionsupporting

confidence: 92%

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Due to genetic and environmental factors, humans display a significant inter-individual variation in inflammatory factors, such as cytokine levels, which can easily span two orders of magnitude. Moreover, PST concentrations that are used in experimental settings are often higher than the 20-80 pg/mL or 4-20 pM PST found in the plasma of healthy humans [32,123,124]. Therefore, the reported effects of PST, such as on cytokine production in mice [115], might not be statistically significant nor functionally relevant in humans.…”

Section: Synopsis and Future Directionsmentioning

confidence: 99%

The immunomodulatory functions of chromogranin A-derived peptide pancreastatin

Ioannidis¹,

Mahata²,

Bogaart³

2022

Peptides

View full text Add to dashboard Cite

“…85 Circulating concentrations of CgA are elevated in a variety of NENs, such as phaeochromocytoma, 77 NENs of the gastrointestinal tract, lung and ovary, 86,87 CgA is also elevated in non-functioning NENs that are not associated with secretion of a particular hormone, and hence do not present with any clinical syndrome. [88][89][90] Elevated circulating concentrations of pancreastatin have also been found in patients with a range of NENs, including NENs arising from the gastrointestinal tract, [91][92][93][94][95] neuroblastoma and ganglioneuroma. 96 Assays specific for the pancreastatin fragment only have been advocated for detecting NENs that have metastasized to the liver.…”

Section: Diagnostic Use Of Cga Cgb and Cartmentioning

confidence: 99%

The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia

et al. 2013

View full text Add to dashboard Cite

Neuroendocrine neoplasia (NEN) is a heterogeneous group of tumours and often represents a therapeutic challenge to clinicians. The peptides chromogranin A (CgA), chromogranin B (CgB) and cocaine-and amphetamine-regulated transcript (CART) are widely distributed throughout the neuroendocrine system. CgA and CgB have been used as general NEN biomarkers for many years, while CART has only recently been identified. Of these biomarkers, CgA is the most commonly used. However, circulating CgA concentrations exhibit considerable intra-individual biological variation, are altered by proton pump inhibitors (PPIs) and somatostatin analogues and are elevated in non-NEN malignancies. Therefore, interpretation of CgA results must be in the context of these confounding factors. The effects of treatment and non-NEN conditions on circulating CgB and CART concentrations are less well understood. CgB is less affected by impaired renal function and PPIs than CgA; while, circulating CART concentrations lack a diurnal variation in humans and are more reliable markers of pancreatic NEN malignancy than CgA. The utility of circulating CgA measurements in NEN prognosis, surveillance and disease recurrence has been widely investigated. However, the utility of CgB and CART in NEN management is yet to be elucidated. Further studies are needed to establish whether CgB and CART are useful alternatives to CgA.

show abstract

Comparison of chromogranin a and pancreastatin levels in plasma of patients with pancreatic islet cell tumor

Cited by 13 publications

References 17 publications

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours

A rapid rise in circulating pancreastatin in response to somatostatin analogue therapy is associated with poor survival in patients with neuroendocrine tumours

The immunomodulatory functions of chromogranin A-derived peptide pancreastatin

The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia

Contact Info

Product

Resources

About